Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Xpress Analyse ApS
APS
Active
CVR 44308908
Østeralle 23
Wholesale of pharmaceutical and medical goods · NACE 4646
Est. 2023
2 employees
www.coronalifecare.dk
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2025
DKK 8K
-96% vs 2024
EBITDA margin
75.4%
-91% vs 2024
Equity ratio
85.3%
Financial strength
Net profit 2025
DKK 5K
-91% vs 2024
EBITDA — year on year
DKK millions
0M
0M
1M
1M
1M
0M
2024
0M
0%
2025
Key figures
Annual report 2025
Revenue
DKK 8K
-96%
EBITDA
DKK 6K
-91%
Net profit
DKK 5K
-91%
Total assets
DKK 111K
-21%
Equity
DKK 94K
+5%
Employees
2
—
Company information
Legal name
Xpress Analyse ApS
CVR number
44308908
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
15. september 2023
Share capital
DKK 40.000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Virksomheden tegnes af Direktør Birte Hedegaard Jensen
Company purpose
Virksomhedens formål er salg af ydelser i forbindelse med support til EKG analyser
Contact
Address
Østeralle 23
Phone
+4546155408
Email
birte@coronalifecare.dk
Website
www.coronalifecare.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Wholesale of pharmaceutical and medical goods
Companies in Syddjurs
All Denmark companies
Revenue
DKK millions
0M
0M
1M
1M
1M
0M
2024
0M
2025
EBITDA
DKK millions
0M
0M
1M
1M
1M
0M
2024
0M
2025
Income statement
DKK thousands
Item
2024
2025
Revenue
186
8
Staff expenses
-123
-2
EBITDA
64
6
Depreciation & amort.
-0
-0
EBIT
64
6
Net financials
-0
0
Profit before tax
64
6
Tax
14
2
Net profit
50
5
Balance sheet
DKK thousands
Item
2024
2025
Total assets
140
111
Equity
90
94
Long-term debt
0
0
Short-term debt
51
16
Total debt
51
16
Financial ratios
5-year trend
EBITDA margin
75.4%
This company
15.8%
Market median
+377% vs market
2024
2025
Equity ratio
85.3%
This company
38.2%
Market median
+123% vs market
2024
2025
Return on equity
4.9%
This company
18.4%
Market median
-73% vs market
2024
2025
Net profit margin
58.7%
This company
8.1%
Market median
+625% vs market
2024
2025
Asset turnover
0.07×
This company
1.12×
Market median
-94% vs market
2024
2025
Debt / equity
0.17×
This company
0.62×
Market median
+73% vs market
2024
2025
Annual reports & filings
Annual report 2025
Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
View
PDF
Annual report 2024
Filed via CVR / Virk · Period 2023-09-15 – 2024-06-30
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Age
Other directorships
BH
Birte Hedegaard Jensen
Management
Management
2023
—
—
Board of directors
Non-executive oversight
Name
Role
Member since
Age
Other directorships
BB
Boye Bilgaard Jensen
Chairman
2023
—
—
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Hedegaard Jensen Holding ApS
Company
100.0%
100.0%
2023
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
Hedegaard Jensen Holding ApS
Xpress Analyse ApS
(this company)
Board network connections
Board members of Xpress Analyse ApS also hold positions in
0
other companies.
Person
Role here
Other companies
Birte Hedegaard Jensen
Management
0 companies
Boye Bilgaard Jensen
Chairman
0 companies